Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
According to Zhihu Finance APP, early-stage biotechnology company TRex Bio Inc., which focuses on autoimmune and inflammatory diseases, has raised $116.7 million through an IPO, with the offering price set at the lower end of its proposed range.
According to a statement released Thursday, the company sold approximately 8.3 million shares at a price of $14 per share. Previously filed documents indicated that the biotech company had set an offering range of $14 to $16 per share.
Based on the IPO offering price, San Francisco-based TRex has a market value of $384 million, calculated according to the number of outstanding shares listed in the documents.
The company's investors include Eli Lilly, SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation, Janus Henderson Investors, Alexandria Venture Investments, Delos Capital, and Polaris Partners. Prior filings indicated that Eli Lilly expressed interest in subscribing for shares in this IPO but does not intend to increase its stake to more than 19.9%.
Strong overall volume, diverging returns
TRex is expected to continue the strong momentum for U.S. healthcare IPOs this year. Compiled data shows that biotech and pharmaceutical IPOs have raised nearly $800 million so far this year, almost six times the amount raised during the same period last year.
However, its pricing reflects the direct manifestation of the "overall boom, internal divergence" pattern seen in biopharma IPOs in 2026: the sector's weighted average return this year is about +55%, but almost all the gains come from "platform-based, multi-pipeline, catalyst-nearing" companies.
Looking at subsequent performance, platform-based, multi-pipeline companies (Parabilis, BillionToOne) rose 66% on their debut; single-asset, single-indication companies (Electra) broke issue price on their first day. Investors now price according to "the specific risks of the story" instead of giving a unified premium to the entire sector.
Furthermore, companies that are closer to binary readouts (about to enter Phase 3, or having already filed for listing) are more sought after; companies whose key data won't be available for more than 18 months typically go without a premium or even break below issue price. Companies like TRex Bio, which are "single-asset, Phase 1, with key data expected only by mid-2027," are a segment that the market has started to specifically price down in the second half of the year. Demand for such offerings is real but relatively shallow, and Eli Lilly's strategic endorsement is only enough to bring the deal to market, not to support a price premium within the proposed range.
The company plans to use the funds raised this time to advance its core candidate drug TRB-061, which is currently in early clinical trials for patients with moderate-to-severe atopic dermatitis. Documents show the company expects to release topline data for this investigational therapy by mid-next year. In addition, the company also plans to launch a Phase 1 clinical trial for TRB-071 in the first half of 2027, targeting inflammatory bowel disease.
In January of this year, TRex raised $50 million through a follow-on tranche of Series B preferred shares, with new investors including Janus Henderson and Balyasny Asset Management.
TRex CEO Johnston Erwin worked at Eli Lilly for 36 years before joining the company and previously led Lilly's internal venture arm, Lilly New Ventures.
Previously filed documents show the company had a net loss of $34.8 million in 2025, compared to a net loss of $3.1 million the previous year.
The offering is being led by JPMorgan, Evercore, Cantor Fitzgerald, Stifel Financial, and Wedbush PacGrow. Shares are expected to begin trading Friday on the Nasdaq Global Select Market under the ticker (TRXB.US).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Reports of iPhone production cuts send Apple shares lower
October 9 – According to Nikkei Asia (link), Apple has asked its suppliers to cut production of the new iPhone 18 Pro model due to weak demand, resulting in Apple (AAPL.O) shares falling 1.8% in premarket trading to $334.21. The report states that, against the backdrop of soaring memory chip costs and rising prices, the component orders for October have been reduced by at least 15% compared to initial requirements. Apple has not yet responded to a Reuters request for comment. The current stock price is about 1% lower than the all-time intraday high of $345.34 reached on September 22. According to data compiled by the London Stock Exchange Group (LSEG), the average rating from 43 analysts covering the stock is "Buy," with a median target price of $330. (For the convenience of non-English speakers, Reuters provides automated translations of its report into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss resulting from use of the automated translation function.)
Citi maintains a “Neutral” rating on DocuSign (DOCU.O): IAM platform migration shows initial effectiveness, double-digit growth still needs "validation"
Citi published a research report maintaining a "Neutral" rating on the e-signature and agreement cloud platform DocuSign, with a target price of $72.
Humana shares soar as it becomes the biggest beneficiary of the 2027 Medicare star ratings.
Reuters, October 9 – In pre-market trading on Friday, shares of Humana (stock code: HUM.N) rose by 15%. Analysts said the health insurer is set to be the biggest beneficiary of the new 2027 Medicare Advantage star ratings. Humana stated that, with improvements in healthcare quality and member experience indicators, 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher by 2027, a substantial jump from 20% in 2026 (link). JPMorgan analysts noted that they had previously projected this ratio to be between 60% and 70%. The U.S. Department of Health and Human Services uses a one- to five-star scale to rate Medicare Advantage and prescription drug plans. Higher ratings lead to government bonuses worth billions of dollars and can help attract more members. Analysts noted that Humana’s ratings performance outpaced its larger competitors: JPMorgan expects the proportion of UnitedHealth Group’s (UNH.N) plans rated four stars or higher to decrease from 81% to about 67%, while CVS Health’s (CVS.N) ratio will fall from 84% to about 70%. The U.S. Department of Health and Human Services said Thursday night that, overall, about 71% (link) of Medicare Advantage prescription drug plan enrollees will be in contracts rated four stars or higher in 2027. Evercore ISI analyst Elizabeth Anderson said that Humana had improved in prescription drug plan quality, health plan quality, and readmission rates. She added, “This improvement reflects management’s increased focus on these metrics over the past year.” Health insurers provide Medicare Advantage plans for the government to adults aged 65 and older and people with disabilities.
Illia Polosukhin: NEAR accounts can achieve quantum resistance through key updates
Crypto prices
More
